We performed susceptibility testing with Shigella sonnei isolates from imported and domestic cases of infection in Japan during 2001 and 2002. Some S. sonnei isolates were resistant to nalidixic acid, tetracycline, and trimethoprim-sulfamethoxazole. Most of the nalidixic acid-resistant strains showed reduced susceptibility to fluoroquinolones but did not show fluoroquinolone resistance.
levofloxacin (LVFX), sparfloxacin (SPFX), cefoperazone (CPZ), ceftriaxone (CTRX), cefotaxime (CTX), and imipenem (IPM) were determined by Etest, and the MIC of trimethoprim-sulfamethoxazole (TS) (1:19) was determined by the broth microdilution method. The susceptibility testing by Etest was carried out according to the manufacturer's instructions, and the susceptibility testing by the broth microdilution method followed the NCCLS method (11) . The primers used for the PCR amplification of the gyrA genes and the sequencing of the quinolone resistance-determining region (QRDR) of the gyrA genes were previously described (7) .
We report here the results of susceptibility and molecular analyses of clinical isolates of S. sonnei recovered from imported and domestic cases during the period 2001 to 2002 in Japan. Fifty-eight strains of S. sonnei isolated in Japan were tested for susceptibility to 18 antimicrobial agents. All of the isolates tested in this study were susceptible to kanamycin, gentamicin, norfloxacin, fosfomycin, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, cefoperazone, ceftriaxone, cefotaxime, and imipenem (Table 1) .
Resistance to chloramphenicol and ampicillin was infrequent (range, 0 to 8%) in both domestic and imported isolates. Resistance to trimethoprim-sulfamethoxazole and tetracycline was highly frequent (69 and 89%, respectively) in imported isolates. In contrast, the frequencies of resistance to trimethoprim-sulfamethoxazole and tetracycline ranged from about 32 to 37% in domestic isolates. We found that 26% of isolates in both imported and domestic cases were NA-resistant strains, and most of them showed reduced susceptibility to several fluoroquinolones (Tables 1 and 2 ). The major patterns of resistance were resistance to TC and TS (36%) and TC, TS, and NA (24%) in imported cases and resistance to NA (21%) and TC and TS (21%) in domestic cases (data not shown).
The MICs of fluoroquinolones were compared between NAresistant and NA-susceptible strains ( Table 2 ). The MICs were higher in the NA-resistant than NA-susceptible strains. Most of the NA-resistant S. sonnei strains showed reduced susceptibility to the fluoroquinolones tested but did not show resistance. The current NCCLS breakpoint for resistance to ciprofloxacin is Ն4 g/ml. Strains for which the MIC of ciprofloxacin was Ն0.125 g/ml and Յ2 g/ml were considered to have reduced susceptibility to ciprofloxacin among the S. enterica serovars Typhi and Paratyphi A (1, 8, 13) , because typhoid fever and paratyphoid fever caused by these strains did not respond to fluoroquinolone therapy when the strains were judged "susceptible" based on the NCCLS breakpoint in susceptibility tests. Similarly, we considered S. sonnei strains for which the MIC of ciprofloxacin was Ն0.125 g/ml and Յ2 g/ml to have reduced susceptibility to ciprofloxacin. Several studies have shown that resistance to nalidixic acid and reduced susceptibility to fluoroquinolones have increased among Shigella spp. (5, 6) . Despite the low level of resistance to fluoroquinolones, the efficacy of fluoroquinolone treatment may be reduced in humans infected with S. sonnei strains that are regarded as having reduced susceptibility to fluoroquinolone, as seen in infections by the isolates of S. enterica serovars Typhi and Paratyphi A with reduced susceptibility to fluoroquinolone. The breakpoint for reduced susceptibility is important when assessing the efficacy of fluoroquinolones. The breakpoint for reduced susceptibility was different for each fluoroquinolone antibiotic. In this study, the breakpoints for reduced susceptibility were 0.125, 0.25, 0.25, 0.125, and 0.064 g/ml for ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, and sparfloxacin, respectively (Table 2) .
In all of the NA-resistant strains, a QRDR in the gyrA gene coding for a region associated with NA resistance was sequenced. All NA-resistant strains had a single point mutation in either codon 83 or 87 of GyrA. All five NA-resistant isolates from domestic cases had the same mutations in codon 83 of GyrA, which led to the replacement of Ser (TCC)-83 with Leu (TGG)-83. Out of 10 NA-resistant isolates from imported cases, five strains had a mutation in codon 83 and the others had a mutation in codon 87 of GyrA. The five NA-resistant isolates from imported cases had the same mutation in codon 83 (Ser to Leu). One strain with a mutation in codon 87 of GyrA had a novel alteration at the codon, which led to replacement of Asp (GAC) with Ala (GCC). This alteration has not been reported in Shigella gyrA mutations previously. The others had a mutation which led to Asp (GAC)-87 being replaced with Tyr (TAC)-87, which has been reported in other papers (4) . The MICs at which 90% and 50% of the isolates tested are inhibited (MIC 90 and MIC 50 , respectively) of several fluoroquinolones for isolates were compared among the strains with mutations in codons 83 and 87 of GyrA (Table 3 ). The MIC 90 and MIC 50 seemed to be slightly lower for the strains with a single mutation in codon 87 than for those with a mutation in codon 83 (Table 3) . We found only one strain which was resistant to NA but highly susceptible to ciprofloxacin and other fluoroquinolones (Table 2) . A genetic analysis revealed this strain to have a mutation in codon 87. Furthermore, we analyzed the parC genes of NA-resistant strains but did not find any mutations responsible for the fluoroquinolone resistance. A mutational analysis of the S. sonnei isolates suggested that the reduced susceptibility to fluoroquinolones was due to mutation of the gyrA gene.
Fluoroquinolones are the first choice for the treatment of shigellosis caused by multidrug-resistant strains. Recently, the emergence of Shigella dysenteriae that is resistant to fluoroquinolones such as ciprofloxacin, norfloxacin, and ofloxacin has been reported from India and Bangradesh (2, 10) . The emergence of ciprofloxacin-resistant Shigella strains is a major problem in the treatment of shigellosis. In this study, we did not find any fluoroquinolone-resistant S. sonnei strains in Japan. The surveillance of the antimicrobial resistance of S. sonnei isolates should be continued, particularly to monitor the emergence of strains which are fully resistant to fluoroquinolones.
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